A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine (20vPnC) and BNT162b2 in Pneumococcal Disease, COVID-19 and SARS-CoV-2 Infection, sponsored by Pfizer. Completed at 27 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-14.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 14 in phase 3, and was the 10th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2021.
This study's enrollment of 570 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 29th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2021, is one of 33 in phase 3, and was the 56th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive an injection of pneumococcal vaccine (20vPnC) and of COVID-19 vaccine (BNT162b2) at the same visit.
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) · Biological: BNT162b2
Participants receive an injection of pneumococcal vaccine (20vPnC) and of saline at the same visit.
Biological: 20-valent pneumococcal conjugate vaccine (20vPnC) · Other: Saline
Participants receive an injection of COVID-19 vaccine (BNT162b2) and of saline at the same visit.
Biological: BNT162b2 · Other: Saline
20-valent pneumococcal conjugate vaccine (20vPnC)
RNA-based SARS-CoV-2 vaccine (BNT162b2)
Normal saline for injection
Percentage of Participants With Local Reactions at Each Injection Site Within 10 Days After Vaccination
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.
Time frame: Within 10 days after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.
Time frame: Within 7 days after vaccination
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: From day of vaccination (Day 1) up to 1 month after vaccination
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination
A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.
Time frame: From day of vaccination (Day 1) up to 6 months after vaccination
Geometric Mean Titers (GMTs) of Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) at 1 Month After Vaccination With 20vPnC
OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.
Time frame: 1 month after vaccination with 20vPnC
Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2
IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.
Time frame: 1 month after vaccination with BNT162b2
Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2
The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.
Time frame: Before vaccination to 1 month after vaccination with BNT162b2
Eligible participants who received 2 doses of ribonucleic acid (RNA)-based COVID-19 vaccine (BNT162b2) at least 6 months previously in study C4591001 (NCT04368728) were stratified by prior pneumococcal vaccine status (no previous pneumococcal vaccine \[naïve\] or receipt of at least 1 dose of a pneumococcal vaccine \[experienced\]) and randomized to 1 of the 3 vaccine groups in this study.
| Milestone | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|---|
| Started | 190 | 191 | 189 |
| Vaccinated | 187 | 187 | 185 |
| Completed | 184 | 177 | 182 |
| Not completed | 6 | 14 | 7 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 3 |
| Withdrew: Physician decision | 0 | 4 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 6 | 1 |
| Withdrew: No longer met eligibility criteria | 1 | 2 | 1 |
| Withdrew: Other | 2 | 1 | 1 |
Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with daily activity, moderate: interfered with daily activity and severe: prevented daily activity. Percentage of participants with local reactions at each injection site within 10 days after vaccination and the associated 2-sided 95% confidence interval (CI) based on the Clopper and Pearson method was presented.
| Percentage of participants | Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site | Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site | 20vPnC Only Group (20vPnC+Saline): 20vPnC Vaccination Site | 20vPnC Only Group (20vPnC+Saline): Saline Vaccination Site | BNT162b2 Only Group (BNT162b2+Saline): BNT162b2 Vaccination Site | BNT162b2 Only Group (BNT162b2+Saline): Saline Vaccination Site |
|---|---|---|---|---|---|---|
| Redness: Any | 8.6 (5.0 to 13.7) | 9.7 (5.9 to 14.9) | 8.1 (4.6 to 13.0) | 0.0 (0.0 to 2.0) | 9.7 (5.9 to 14.9) | 2.7 (0.9 to 6.2) |
| Redness: Mild | 5.9 (3.0 to 10.4) | 5.9 (3.0 to 10.4) | 4.3 (1.9 to 8.3) | 0.0 (0.0 to 2.0) | 6.5 (3.4 to 11.1) | 2.2 (0.6 to 5.4) |
| Redness: Moderate | 2.7 (0.9 to 6.2) | 3.2 (1.2 to 6.9) | 3.2 (1.2 to 6.9) | 0.0 (0.0 to 2.0) | 2.7 (0.9 to 6.2) | 0.5 (0.0 to 3.0) |
| Redness: Severe | 0.0 (0.0 to 2.0) | 0.5 (0.0 to 3.0) | 0.5 (0.0 to 3.0) | 0.0 (0.0 to 2.0) | 0.5 (0.0 to 3.0) | 0.0 (0.0 to 2.0) |
| Swelling: Any | 8.1 (4.6 to 13.0) | 9.7 (5.9 to 14.9) | 8.6 (5.0 to 13.6) | 0.0 (0.0 to 2.0) | 11.4 (7.2 to 16.8) | 1.1 (0.1 to 3.9) |
| Swelling: Mild | 5.4 (2.6 to 9.7) | 5.9 (3.0 to 10.4) | 5.4 (2.6 to 9.7) | 0.0 (0.0 to 2.0) | 6.5 (3.4 to 11.1) | 0.0 (0.0 to 2.0) |
| Swelling: Moderate | 2.7 (0.9 to 6.2) | 3.8 (1.5 to 7.6) | 3.2 (1.2 to 6.9) | 0.0 (0.0 to 2.0) | 4.9 (2.2 to 9.0) | 1.1 (0.1 to 3.9) |
| Swelling: Severe | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) |
| Pain at injection site: Any | 73.0 (66.0 to 79.2) | 72.4 (65.4 to 78.7) | 60.2 (52.8 to 67.3) | 9.7 (5.8 to 14.9) | 67.6 (60.3 to 74.3) | 16.8 (11.7 to 22.9) |
| Pain at injection site: Mild | 55.1 (47.7 to 62.4) | 56.8 (49.3 to 64.0) | 52.2 (44.7 to 59.5) | 9.7 (5.8 to 14.9) | 50.3 (42.8 to 57.7) | 16.2 (11.2 to 22.3) |
| Pain at injection site: Moderate | 17.8 (12.6 to 24.1) | 15.7 (10.8 to 21.7) | 7.0 (3.8 to 11.7) | 0.0 (0.0 to 2.0) | 17.3 (12.1 to 23.5) | 0.5 (0.0 to 3.0) |
| Pain at injection site: Severe | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 1.1 (0.1 to 3.8) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) |
Systemic events including fever, fatigue, headache, chills, muscle pain and joint pain were recorded by participants using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Percentage of participants with systemic events within 7 days after vaccination and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.
| Percentage of participants | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|---|
| Fever: >=38.0 degree C | 13.0 (8.5 to 18.7) | 1.1 (0.1 to 3.8) | 8.6 (5.0 to 13.7) |
| Fever: >=38.0 degree C to 38.4 degree C | 7.0 (3.8 to 11.7) | 0.5 (0.0 to 3.0) | 2.7 (0.9 to 6.2) |
| Fever: >38.4 degree C to 38.9 degree C | 5.4 (2.6 to 9.7) | 0.5 (0.0 to 3.0) | 4.9 (2.2 to 9.0) |
| Fever: >38.9 degree C to 40.0 degree C | 0.5 (0.0 to 3.0) | 0.0 (0.0 to 2.0) | 1.1 (0.1 to 3.9) |
| Fever: >40.0 degree C | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) |
| Fatigue: Any | 54.1 (46.6 to 61.4) | 36.0 (29.1 to 43.4) | 54.6 (47.1 to 61.9) |
| Fatigue: Mild | 17.8 (12.6 to 24.1) | 23.7 (17.7 to 30.4) | 27.0 (20.8 to 34.0) |
| Fatigue: Moderate | 33.0 (26.3 to 40.3) | 12.4 (8.0 to 18.0) | 24.9 (18.8 to 31.7) |
| Fatigue: Severe | 3.2 (1.2 to 6.9) | 0.0 (0.0 to 2.0) | 2.7 (0.9 to 6.2) |
| Headache: Any | 30.3 (23.7 to 37.4) | 17.2 (12.1 to 23.4) | 33.0 (26.3 to 40.3) |
| Headache: Mild | 17.8 (12.6 to 24.1) | 14.5 (9.8 to 20.4) | 24.9 (18.8 to 31.7) |
| Headache: Moderate | 11.9 (7.6 to 17.4) | 2.7 (0.9 to 6.2) | 7.6 (4.2 to 12.4) |
| Headache: Severe | 0.5 (0.0 to 3.0) | 0.0 (0.0 to 2.0) | 0.5 (0.0 to 3.0) |
| Chills: Any | 26.5 (20.3 to 33.5) | 7.0 (3.8 to 11.7) | 22.2 (16.4 to 28.8) |
| Chills: Mild | 18.4 (13.1 to 24.7) | 5.9 (3.0 to 10.3) | 12.4 (8.0 to 18.1) |
| Chills: Moderate | 6.5 (3.4 to 11.1) | 1.1 (0.1 to 3.8) | 7.6 (4.2 to 12.4) |
| Chills: Severe | 1.6 (0.3 to 4.7) | 0.0 (0.0 to 2.0) | 2.2 (0.6 to 5.4) |
| Muscle pain: Any | 32.4 (25.7 to 39.7) | 14.5 (9.8 to 20.4) | 31.9 (25.2 to 39.1) |
| Muscle pain: Mild | 17.3 (12.1 to 23.5) | 10.2 (6.3 to 15.5) | 15.7 (10.8 to 21.7) |
| Muscle pain: Moderate | 14.1 (9.4 to 19.9) | 4.3 (1.9 to 8.3) | 15.1 (10.3 to 21.1) |
| Muscle pain: Severe | 1.1 (0.1 to 3.9) | 0.0 (0.0 to 2.0) | 1.1 (0.1 to 3.9) |
| Joint pain: Any | 26.5 (20.3 to 33.5) | 9.1 (5.4 to 14.2) | 24.9 (18.8 to 31.7) |
| Joint pain: Mild | 15.1 (10.3 to 21.1) | 5.4 (2.6 to 9.7) | 15.1 (10.3 to 21.1) |
| Joint pain: Moderate | 11.4 (7.2 to 16.8) | 3.8 (1.5 to 7.6) | 9.7 (5.9 to 14.9) |
| Joint pain: Severe | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) | 0.0 (0.0 to 2.0) |
An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with AEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Percentage of participants | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination | 5.3 (2.6 to 9.6) | 4.3 (1.9 to 8.3) | 6.5 (3.4 to 11.1) |
A SAE was defined as any untoward medical occurrence that, at any dose, resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or that was considered to be an important medical event. Percentage of participants with SAEs and the associated 2-sided 95% CI based on the Clopper and Pearson method was presented.
| Percentage of participants | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination | 0.5 (0.0 to 2.9) | 1.1 (0.1 to 3.8) | 2.7 (0.9 to 6.2) |
OPA titers were measured from serum samples for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F,8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the OPA titers and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and 20vPnC only group (20vPnC + saline) as specified in protocol.
| Titer | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline |
|---|---|---|
| Serotype 1 | 142 (116 to 176) | 131 (106 to 162) |
| Serotype 3 | 49 (42 to 56) | 52 (44 to 61) |
| Serotype 4 | 609 (484 to 766) | 573 (447 to 734) |
| Serotype 5 | 81 (65 to 100) | 98 (80 to 120) |
| Serotype 6A | 1377 (1058 to 1792) | 1317 (1042 to 1665) |
| Serotype 6B | 1449 (1153 to 1821) | 1478 (1207 to 1810) |
| Serotype 7F | 977 (836 to 1142) | 1102 (951 to 1275) |
| Serotype 8 | 299 (235 to 381) | 344 (274 to 431) |
| Serotype 9V | 1722 (1365 to 2172) | 1531 (1210 to 1936) |
| Serotype 10A | 2252 (1751 to 2898) | 2644 (2023 to 3456) |
| Serotype 11A | 1875 (1414 to 2488) | 1932 (1445 to 2583) |
| Serotype 12F | 2165 (1668 to 2809) | 2211 (1695 to 2885) |
| Serotype 14 | 709 (572 to 879) | 640 (528 to 775) |
| Serotype 15B | 1520 (1092 to 2117) | 1852 (1377 to 2491) |
| Serotype 18C | 1059 (869 to 1290) | 846 (684 to 1046) |
| Serotype 19A | 637 (520 to 781) | 530 (436 to 644) |
| Serotype 19F | 305 (242 to 383) | 377 (299 to 476) |
| Serotype 22F | 5225 (3931 to 6943) | 4464 (3354 to 5942) |
| Serotype 23F | 336 (251 to 450) | 385 (283 to 524) |
| Serotype 33F | 4907 (3813 to 6316) | 5544 (4234 to 7261) |
IgG levels were measured in serum samples using severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length S-binding assay. GMCs and 2-sided CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in protocol.
| Units per milliliter | Coadministration Group: 20vPnC+BNT162b2 | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|
| Geometric Mean Concentration (GMC) of Full-Length S-Binding Immunoglobulin G (IgG) Levels at 1 Month After Vaccination With BNT162b2 | 29114 (26120 to 32451) | 26655 (24003 to 29599) |
The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from before to approximately 1 month after vaccination. GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs and based on the Student t distribution. Data for this outcome measure was planned to be analyzed for coadministration group (20vPnC + BNT162b2) and BNT162b2 only group (BNT162b2 + saline) as specified in the protocol.
| Fold rise | Coadministration Group: 20vPnC+BNT162b2 | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|
| Geometric Mean Fold Rise (GMFR) of Full-Length S-Binding IgG Levels From Before Vaccination to 1 Month After Vaccination With BNT162b2 | 35.5 (30.9 to 40.7) | 39.0 (33.5 to 45.5) |
Collected over Systematic assessment: local reactions recorded within 10 days after vaccination, and systemic events recorded within 7 days after vaccination; Non-systematic assessment: SAEs recorded from day of vaccination (Day 1) up to 6 months after vaccination and other AEs recorded from Day 1 up to 1 month after vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Coadministration Group: 20vPnC+BNT162b2 | 1/187 (0.5%) | 1/187 (0.5%) | 157/187 (84%) |
| 20vPnC Only Group: 20vPnC+Saline | 0/187 (0%) | 2/187 (1.1%) | 137/187 (73.3%) |
| BNT162b2 Only Group: BNT162b2+Saline | 0/185 (0%) | 5/185 (2.7%) | 149/185 (80.5%) |
| Event | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/187 | 0/187 | 1/185 |
| Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/187 | 0/187 | 1/185 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/187 | 0/187 | 1/185 |
| Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/187 | 0/187 | 1/185 |
| Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/187 | 0/187 | 1/185 |
| Acute kidney injuryRenal and urinary disorders | 0/187 | 0/187 | 1/185 |
| Angina unstableCardiac disorders | 0/187 | 1/187 | 0/185 |
| Duodenal perforationGastrointestinal disorders | 1/187 | 0/187 | 0/185 |
| GlioblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/187 | 1/187 | 0/185 |
| Event | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline |
|---|---|---|---|
| Injection site pain (PAIN)General disorders | 146/187 | 115/187 | 133/185 |
| Fatigue (FATIGUE)General disorders | 100/187 | 67/187 | 101/185 |
| Headache (HEADACHE)Nervous system disorders | 56/187 | 32/187 | 61/185 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 60/187 | 27/187 | 59/185 |
| Chills (CHILLS)General disorders | 49/187 | 13/187 | 41/185 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 49/187 | 17/187 | 46/185 |
| Injection site erythema (REDNESS)General disorders | 26/187 | 15/187 | 22/185 |
| Injection site swelling (SWELLING)General disorders | 26/187 | 16/187 | 21/185 |
| Pyrexia (FEVER)General disorders | 24/187 | 2/187 | 16/185 |
| Urinary tract infectionInfections and infestations | 2/187 | 0/187 | 1/185 |
Safety population included all participants who received at least 1 dose of the study intervention and had safety follow-up after vaccination.
| Age, Continuous(Years) | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline | Total |
|---|---|---|---|---|
| Mean | 71.0 ± 4.22 | 71.8 ± 4.94 | 71.8 ± 4.95 | 71.5 ± 4.72 |
| Sex: Female, Male(Participants) | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline | Total |
|---|---|---|---|---|
| Female | 89 | 75 | 77 | 241 |
| Male | 98 | 112 | 108 | 318 |
| Ethnicity (NIH/OMB)(Participants) | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline | Total |
|---|---|---|---|---|
| Hispanic or Latino | 28 | 26 | 25 | 79 |
| Not Hispanic or Latino | 159 | 161 | 160 | 480 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Coadministration Group: 20vPnC+BNT162b2 | 20vPnC Only Group: 20vPnC+Saline | BNT162b2 Only Group: BNT162b2+Saline | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| Asian | 10 | 5 | 9 | 24 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 8 | 7 | 10 | 25 |
| White | 164 | 172 | 165 | 501 |
| More than one race | 4 | 2 | 0 | 6 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2021 to primary completion in Dec 2021, 6 months.
Results were first posted in Dec 2022, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 6 months is below that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pneumococcal 20-Valent Conjugate Vaccine · BNT162 Vaccine